Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
First-line benmelstobart plus anlotinib versus sunitinib in advanced kidney cancer
A new immunotherapy called benmelstobart, which blocks the action of [...]
New immunotherapy for metastatic kidney cancer could help improve outcomes
Researchers from the University of California in Los Angeles (UCLA) [...]
One Cancer Voice urges government to deliver an ambitious, fully-funded National Cancer Plan
Action Kidney Cancer united with over 60 national charities as [...]
Vigorous exercise as a potential risk factor in renal medullary carcinoma
Renal medullary carcinoma (RMC) is an aggressive and rare type [...]
Stereotactic ablative radiotherapy (SABR) for advanced kidney cancer
Stereotactic ablative body radiotherapy (SABR) uses an intense beam of radiation focused [...]
The Yorkshire Kidney Screening Trial
The Yorkshire Kidney Screening Trial is the first study to [...]
Minimally invasive, maximally effective: The rise of Interventional Oncology
Interventional oncology is a type of interventional radiology. It is [...]
Combination treatment shows benefits in rare, aggressive kidney cancer
Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare [...]
Circulating tumour DNA (ctDNA) as a test for kidney cancer
When a tumour grows it 'sheds' small pieces of tumour [...]
